Inventiva S.A. (IVA)
Automate Your Wheel Strategy on IVA
With Tiblio's Option Bot, you can configure your own wheel strategy including IVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IVA
- Rev/Share 0.3708
- Book/Share -2.0516
- PB -1.4435
- Debt/Equity -0.5094
- CurrentRatio 0.9236
- ROIC -24.5281
- MktCap 411897822.336
- FreeCF/Share -0.7058
- PFCF -11.2261
- PE -1.4776
- Debt/Assets 0.4567
- DivYield 0
- ROE 1.1221
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | IVA | TD Cowen | -- | Buy | -- | $10 | Feb. 21, 2025 |
News
Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Inventiva (IVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Inventiva reports 2025 First Quarter Financial Information¹
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported financial information for the first quarter of 2025, including its cash, cash equivalents and revenues.
Read More
Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders' Meeting.
Read More
Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript
Published: March 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Inventiva S.A. (NASDAQ:IVA ) Q4 2024 Earnings Call March 27, 2025 8:00 AM ET Company Participants Frédéric Cren - CEO Jean Volatier - CFO Pierre Broqua - CSO Conference Call Participants Unidentified Analyst - TD Cowen Unidentified Analyst - Jefferies & Co. Annabel Samimy - Stifel Ed Arce - HC Wainwright Jacob Mekhael - KBC Securities Rami Katkhuda - LifeSci Capital Unidentified Analyst - UBS Operator Good day and thank you for standing by.
Read More
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Daix (France), New York City (New York, United States), February 26, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the publication in Biomedicine & Pharmacotherapy, a peer-reviewed, scientific journal, of the results from a preclinical study demonstrating that lanifibranor may reduce Portal Hypertension (“PH”).
Read More
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Daix (France), New York City (New York, United States), Tokyo (Japan), February 20, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, and Hepalys Pharma, Inc. (“Hepalys”), a company incorporated in Japan and founded by Catalys Pacific, announced today the initiation of the clinical development program of lanifibranor in Japan with the first Japanese participant dosed in a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics (“PK”) …
Read More
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
Daix (France), New York City (New York, United States), February 10, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), and other diseases with significant unmet medical needs, today reported certain preliminary unaudited financial results for the full year ended December 31, 2024, including cash, cash equivalents, and revenues, and also provided a business update.
Read More
About Inventiva S.A. (IVA)
- IPO Date 2020-07-10
- Website https://www.inventivapharma.com
- Industry Biotechnology
- CEO Mr. Frederic Cren
- Employees 114